Literature DB >> 18588787

[Evaluation of benign paroxysmal positional vertigo in primary health-care and first level specialist care].

Paz Pérez1, Covadonga Manrique, María Jesús Alvarez, Patricia Aldama, Juan Carlos Alvarez, M Luisa Fernández, Juan Carlos Méndez.   

Abstract

INTRODUCTION: Benign paroxysmal positional vertigo (BPPV) is the most common cause of vestibular vertigo, but it is not well known in routine clinical practice.
OBJECTIVE: To determine the awareness of BPPV outside the ENT clinic. PATIENTS AND
METHOD: Retrospective study of sixty-nine patients treated for BPPV between June 2005 and December 2006 at the specialist clinic. We analyzed the routes and details for their referral and the time elapsed since the start of the symptoms.
RESULTS: 42 patients (61 %) were referred through the conventional route (primary health-care or non-hospital ENT); 17 patients (25 %) came from the emergency room (one third of them were admitted); the remainder were patients hospitalized for some other problem (5 %) or informal consultations (9 %). Only one patient had been referred with a specific diagnosis of BPPV. The onset of vertigo symptoms before treatment was, on average, 20 weeks (SD, 32 weeks) and was significantly longer among patients coming from primary care (28 weeks) as compared with the other groups (P < .01, Kruskall-Wallis test). The mean time to referral was shorter among patients with idiopathic BPPV or with BPPV secondary to recurrent vestibulopathy whereas it was more prolonged among patients with a concomitant pathology capable of justifying the presence of positional symptoms, such as vestibular neuritis or post-traumatic BPPV (P < .01, Kruskall-Wallis test). The medical cost of treating BPPV prior to referral has been calculated at euro364 per individual (mostly for non-specific medical treatments) instead of the euro136 needed for effective positional treatment.
CONCLUSIONS: BPPV continues to be a poorly understood pathology outside specialist neuro-otologic clinics, leading to delays in diagnosis and treatment, as well as the unnecessary consumption of resources.

Entities:  

Mesh:

Year:  2008        PMID: 18588787

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  5 in total

1.  Effectiveness of the Epley manoeuvre in posterior canal benign paroxysmal positional vertigo: a randomised clinical trial in primary care.

Authors:  José Luis Ballvé; Ricard Carrillo-Muñoz; Yolanda Rando-Matos; Iván Villar; Oriol Cunillera; Jesús Almeda; Estrella Rodero; Xavier Monteverde; Carles Rubio; Noemí Moreno; Olga Lucia Arias; Carlos Martin; Rafael Azagra
Journal:  Br J Gen Pract       Date:  2018-12-03       Impact factor: 5.386

2.  Health services utilization of patients with vertigo in primary care: a retrospective cohort study.

Authors:  Eva Grill; Michael Strupp; Martin Müller; Klaus Jahn
Journal:  J Neurol       Date:  2014-05-11       Impact factor: 4.849

3.  The Patterns of Recurrences in Idiopathic Benign Paroxysmal Positional Vertigo and Self-treatment Evaluation.

Authors:  Hyo-Jung Kim; Ji-Soo Kim
Journal:  Front Neurol       Date:  2017-12-15       Impact factor: 4.003

4.  Probable benign paroxysmal positional vertigo, spontaneously resolved: Incidence in medical practice, patients' characteristics and the natural course.

Authors:  M G Álvarez-Morujo de Sande; R González-Aguado; G Guerra-Jiménez; E Domènech-Vadillo; H Galera-Ruiz; E Figuerola-Massana; Á Ramos-Macías; C Morales-Angulo; A J Martín-Mateos; E Domínguez-Durán
Journal:  J Otol       Date:  2019-04-25

5.  Effectiveness of the Epley's maneuver performed in primary care to treat posterior canal benign paroxysmal positional vertigo: study protocol for a randomized controlled trial.

Authors:  José Luis Ballve Moreno; Ricard Carrillo Muñoz; Iván Villar Balboa; Yolanda Rando Matos; Olga Lucia Arias Agudelo; Asha Vasudeva; Olga Bigas Aguilera; Jesús Almeda Ortega; Alicia Capella Guillén; Clara Johanna Buitrago Olaya; Xavier Monteverde Curto; Estrella Rodero Perez; Carles Rubio Ripollès; Pamela Catalina Sepulveda Palacios; Noemí Moreno Farres; Anabella María Hernández Sánchez; Carlos Martin Cantera; Rafael Azagra Ledesma
Journal:  Trials       Date:  2014-05-21       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.